Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • HCW Biologics' Shares Outstanding (Weighted Average) rose 13901.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 13901.27%. This contributed to the annual value of $38.8 million for FY2024, which is 797.0% up from last year.
  • As of Q3 2025, HCW Biologics' Shares Outstanding (Weighted Average) stood at $2.3 million, which was up 13901.27% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Shares Outstanding (Weighted Average) peaked at $44.7 million during Q1 2025, and registered a low of $945585.0 during Q2 2024.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $24.8 million, with a median of $35.8 million in 2022.
  • As far as peak fluctuations go, HCW Biologics' Shares Outstanding (Weighted Average) surged by 63923.52% in 2022, and later plummeted by 9736.8% in 2024.
  • Quarter analysis of 5 years shows HCW Biologics' Shares Outstanding (Weighted Average) stood at $18.8 million in 2021, then surged by 90.84% to $35.8 million in 2022, then increased by 0.3% to $35.9 million in 2023, then grew by 7.97% to $38.8 million in 2024, then plummeted by 94.17% to $2.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $2.3 million for Q3 2025, versus $1.8 million for Q2 2025 and $44.7 million for Q1 2025.